Ruti Aga and the Six-Year Arithmetic: Two Years for the Drug, Four for a Prescription From a Clinic That Did Not Exist

Six years. That was the number at the top of the Athletics Integrity Unit (AIU) statement released on Thursday. Ruti Aga, Ethiopia, marathon, 32. Most headlines stopped there — marathon runner banned for six years. Read the statement twice and six is not a single figure. It is two plus four. Two years for methylprednisolone, meaning the presence of the substance. Four years for tampering, meaning a prescription issued from a clinic that did not exist, written by a person with no medical registration, who claimed he used an old prescription pad from a former workplace, which that clinic explicitly disowned.

Three independent verification failures. In one document.

Every match sheet is a ritual: observe, record, then doubt. I picked up that habit on the night of Berlin 2026, when Aga finished second in 2:18:34 behind Gladys Cherono. A year later she won Tokyo in 2:20:40. Neither figure appears in the AIU statement; both come from external records and I keep them inside the bracket of recall rather than fact. What the statement does establish is that this case contains no performance data at all. The half marathon she won in China in March carries no mark: no field quality, no splits, no season's best. Any performance claim here would be fabrication. The result is analytically secondary; the disqualification is the story.

Context: the depth in which even a 2:18 runner is optional

Ethiopian women's marathoning has a sub-2:14 tier, a world-record class near 2:11, and a large band between 2:18 and 2:20 whose occupants cannot demand national selection, only hope for it. Aga's three World Marathon Majors second places sit in that band — commercial-tier results, never championship conversions. That distinction matters: her removal moves Ethiopia's medal capacity by no measurable margin. In any calculation it is approximately zero.

The second piece of context is the economic layer the March race belongs to. Between Majors, the Asian label-race circuit is a clean income tier for East African marathoners: appearance fee, managed logistics, low risk. It is also now the AIU's highest-yield sampling ground. The appearance-fee economy and the testing economy are colliding inside the same races. Winning a half marathon in China implies a World Athletics Label-tier elite women's field with in-competition testing — otherwise no AIU sample would exist.

The third piece of context is the rule, and this is where the reporting went wrong.

What the media got wrong: not a steroid, a glucocorticoid

The source report called methylprednisolone a prohibited steroid and said WADA classes it as performance enhancing. That is imprecise. Methylprednisolone is a glucocorticoid, WADA Prohibited List class S9, not an anabolic steroid under S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The distinction is not decorative; it is the legal hinge of the entire case.

A therapeutic knee injection is entirely legal out of competition. It becomes a violation only when residues are present in-competition. And in road racing the in-competition window opens at 23:59 the day before the race, which means an injection given several days earlier can still be caught. That is the technical window in which this case was built or broken.

I build the frame first, then let the outlier speak. Here the frame says Aga had a legitimate defence: route, timing, medical necessity, all arguable. Intra-articular methylprednisolone for knee synovitis is standard sports-medicine practice in distance runners; it is not a hidden trick. The moment she forged the prescription, she destroyed the one defence that could have worked.

The arithmetic: what two plus four tells us

Two years for presence, four for tampering. Within the Code's standard architecture the sum is internally consistent. A two-year presence sanction generally signals a specified substance finding without proven intent, and four years is the standard tampering sanction. The real information is not in the six but in the two: the panel rejected the no-significant-fault mitigation that would have reduced the presence sanction further. With genuine medical records and a coherent route-and-timing explanation, the outcome could have landed at a reprimand or a much shorter period, and no tampering charge would have existed at all.

There is a further subtlety. A forged document is itself circumstantial evidence of concealment intent, yet it did not aggravate the presence sanction. The panel kept the two accounts separate — substance in one, paperwork in the other. Technically clean, practically brutal, because for the athlete the outcomes compound into six years.

Backdating to 10 September is a procedural benefit, not a reduction. Provisional suspension time counts against the ban, so in real terms she gained nothing. Age 32, ban six years, likely return age 38. In Ethiopia's women's marathon depth, a 38-year-old returnee with a doping record has no selection pathway. Technically the sanction is six years; functionally it is a lifetime ban.

The three failures of one document

First, the clinic's existence. Second, the individual's medical registration. Third, the old prescription pad. All three were verified independently, at different levels, by different people, and all three collapsed. A careless forgery does not fail in three places. One that fails in three places was produced by a system with no verification layer at all.

That is the system signal, and it concerns the medical structure around the athlete rather than the athlete. An athlete with a credentialed team physician has two routes: apply for a therapeutic use exemption, or observe the route-specific washout period. Neither appears here. What appears is a family member described as a doctor, who was not one. Forgery is the downstream symptom; an absent governance structure is the upstream cause.

And the knee? My reading is that the pathology is chronic and career-long rather than an acute event in March. The attempt to manufacture a paper trail points to a repeated pattern of informal treatment rather than a single lapse. That is inference, not finding, and I label it as inference.

One more layer goes unexamined in the statement. The four-year tampering sanction arises from an interview, not from a document alone — meaning from statements made under questioning. Language and translation conditions in AIU interviews with East African athletes have been a recurring point of contention. That does not make the sanction wrong. It means the heaviest part of the penalty was decided in a room where the evidence was testimony, not paper.

What survives, and what does not

The 2026 Tokyo Marathon title survives. The violation is anchored to a March race in a later year, and absent a finding of earlier use, results before that date are not automatically annulled. The statement does not specify the disqualification scope, and I will not fill that gap. Standard AIU practice is clear enough: the competition where the sample was collected is disqualified, with its prize money, plus ranking points accrued afterwards. The March title, the appearance fee and the points are all likely gone.

What does not survive is the 2028 Olympic cycle. Six years from 10 September removes it entirely.

Contrarian: six years is not the price of the drug

Here is the uncomfortable part. Methylprednisolone has no proven endurance-performance benefit. It can reduce knee inflammation and allow training to continue, but a direct performance claim is unproven. The six-year sanction is therefore not a penalty for an advantage. It is a penalty for a document. That gap matters, because the anti-doping system here imposed its heaviest tariff on the one thing it never actually detected — the fraud — while the thing it did detect has no demonstrated effect on the sport.

Two opposite readings will follow, and both will be made. One says the AIU is rigorous, it audits paperwork, and that should be the standard. The other says six years for a substance with no proven benefit is evidence of disproportionate enforcement against African road runners. I find the second weaker here, for a plain reason: most of the penalty came from tampering, not from the substance. The door is not closed to an athlete who arrives with genuine medical records.

Where caution is warranted is between correlation and causation. A cluster of East African road-racing cases does not prove that doping in road running has risen. It shows something else: the enforcement frontier has moved from detection to verification. The old question was what is in the sample. The new question is what is in the paperwork. Aga's case is a clean specimen of that new boundary, and therefore a preview of many more.

And read through an attention audit, the coverage this received sat well below its actual weight. This is not one marathoner's ban. It is a documented case of medical-governance failure in which three verification layers fall at once — the kind of story that would generate a week of debate if it involved a cricket team's physio.

Finally, the three silvers. Aga's three World Marathon Majors second places were what they were before this ban and will be what they are after it. They were never championship medals, and a suspension does not convert them into tragedy or into podiums. Keeping the near-miss ledger exact is the point; exactness does the emotional work, not inflation.

What to watch next

The first signal is the cluster. One informal medical network serves many athletes in one training group. If a prescription was forged in one case, other cases passing through the same network are likely to have paperwork problems. Watch the number of tampering-based decisions over the next few months, not just substance-based ones.

The second is the Chinese label circuit. Large appearance-fee budgets, deep East African elite fields and AIU testing intersect there, which makes that tier the highest integrity-risk zone on the calendar.

The third is the silence. No Ethiopian federation statement appears in the release; only the AIU speaks. When a national federation stays quiet, reform pressure lands entirely on an external body — and an external body can impose sanctions but cannot appoint a team physician.

The real fix is not more testing. Testing is already happening and will continue. The real fix is TUE infrastructure: a structure in which a marathoner who needs a knee injection has a route other than forging paper. Until that route exists, the next story will read the same — correct arithmetic, wrong question, and one career spent on one prescription.